Should neurologists measure fibrinogen concentrations?

Journal of the Neurological Sciences

Volumn 246, Issue 1-2, 2006, Pages 5-9

  Di Napoli, Mario ^a,b   Papa, Francesca ^b  

^a SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

^b SMDN Center for Cardiovasc Medicine   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; C REACTIVE PROTEIN; FIBRINOGEN; POLYPEPTIDE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; DIAGNOSTIC PROCEDURE; EDITORIAL; EMBOLISM; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; GENE INTERACTION; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL PRACTICE; MEDICAL SPECIALIST; PATHOGENESIS; POLYMERIZATION; PRIORITY JOURNAL;

BIOLOGICAL MARKERS; CEREBROVASCULAR ACCIDENT; FIBRINOGEN; GENE EXPRESSION; HUMANS; TREATMENT OUTCOME;

EID: 33744931883     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2006.03.005     Document Type: Editorial

References (31)

1. Danesh J., Lewington S., Thompson S.G., Lowe G.D., Collins R., Kostis J.B., et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 294 (2005) 1799-1809
2. Lowe G.D., Rumley A., Whincup P.H., and Danesh J. Hemostatic and rheological variables and risk of cardiovascular disease. Semin Vasc Med 2 (2002) 429-439
3. Southan C., Thompson E., and Lane D.A. Direct analysis of plasma fibrinogen-derived fibrinopeptides by high performance liquid chromatography: investigation of A alpha-chain N-terminal heterogeneity. Thromb Haemost 56 (1986) 193-197
4. Lowe G.D. Fibrin D-dimer and cardiovascular risk. Semin Vasc Med 5 (2005) 387-398
5. Lowe G.D. The relationship between infection, inflammation, and cardiovascular disease: an overview. Ann Periodontol 6 (2001) 1-8
6. Sakakibara H., Fujii C., and Naito M. Plasma fibrinogen and its association with cardiovascular risk factors in apparently healthy Japanese subjects. Heart Vessels 19 (2004) 144-148
7. Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost 89 (2003) 601-609
8. Woodhouse P.R., Khaw K.T., Plummer M., Foley A., and Meade T.W. Seasonal variations of plasma fibrinogen and factor VII activity in the elderly: winter infections and death from cardiovascular disease. Lancet 343 (1994) 435-439
9. Crawford V.L., McNerlan S.E., and Stout R.W. Seasonal changes in platelets, fibrinogen and factor VII in elderly people. Age Ageing 32 (2003) 661-665
10. de Maat M.P., Kastelein J.J., Jukema J.W., Zwinderman A.H., Jansen H., Groenemeier B., et al. -455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group. Arterioscler Thromb Vasc Biol 18 (1998) 265-271
11. Kessler C., Spitzer C., Stauske D., Mende S., Stadlmuller J., Walther R., et al. The apolipoprotein E and beta-fibrinogen G/A-455 gene polymorphisms are associated with ischemic stroke involving large-vessel disease. Arterioscler Thromb Vasc Biol 17 (1997) 2880-2884
12. Carter A.M., Catto A.J., Bamford J.M., and Grant P.J. Gender-specific associations of the fibrinogen B beta 448 polymorphism, fibrinogen levels, and acute cerebrovascular disease. Arterioscler Thromb Vasc Biol 17 (1997) 589-594
13. Turaj W., Slowik A., Dziedzic T., Puyk R., Adamski M., Strojny J., and Szczudlik A. Increased plasma fibrinogen predicts one-year mortality in patients with acute ischemic stroke. J Neurol Sci 246 (2006) 13-19 10.1016/j.jns.2006.01.020 (this issue)
14. Woodward M., Lowe G.D., Campbell D.J., Colman S., Rumley A., Chalmers J., et al. Associations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke 36 (2005) 2143-2147
15. Sacco R.L., Adams R., Albers G., Alberts M.J., Benavente O., Furie K., et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 37 (2006) 577-617
16. Gaffney P.J., and Wong M.Y. Collaborative study of a proposed international standard for plasma fibrinogen measurement. Thromb Haemost 68 (1992) 428-432
17. Maresca G., Di Blasio A., Marchioli R., and Di Minno G. Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol 19 (1999) 1368-1377
18. Sweetnam P.M., Yarnell J.W., Lowe G.D., Baker I.A., O'Brien J.R., Rumley A., et al. The relative power of heat-precipitation nephelometric and clottable (Clauss) fibrinogen in the prediction of ischaemic heart disease: the Caerphilly and Speedwell studies. Br J Haematol 100 (1998) 582-588
19. Hassan J.H., Chelucci C., Peschle C., and Sorrentino V. Transforming growth factor beta (TGF-beta) inhibits expression of fibrinogen and factor VII in a hepatoma cell line. Thromb Haemost 67 (1992) 478-483
20. Di Napoli M., Schwaninger M., Cappelli R., Ceccarelli E., Di Gianfilippo G., Donati C., et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke 36 (2005) 1316-1329
21. Sabeti S., Exner M., Mlekusch W., Amighi J., Quehenberger P., Rumpold H., et al. Prognostic impact of fibrinogen in carotid atherosclerosis: nonspecific indicator of inflammation or independent predictor of disease progression?. Stroke 36 (2005) 1400-1404
22. Di Napoli M., Papa F., and Bocola V. C-reactive protein in ischemic stroke: an independent prognostic factor. Stroke 32 (2001) 917-924
23. Di Napoli M., Papa F., and Bocola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke 32 (2001) 133-138
24. Di Napoli M., and Papa F. Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Stroke 33 (2002) 1763-1771
25. van Goor M.P., Gomez-Garcia E.B., Leebeek F.W., Brouwers G.J., Koudstaal P.J., and Dippel D.W. The -148 C/T fibrinogen gene polymorphism and fibrinogen levels in ischaemic stroke: a case-control study. J Neurol Neurosurg Psychiatry 76 (2005) 121-123
26. Hossmann K.A., and Hossmann V. Coagulopathy following experimental cerebral ischemia. Stroke 8 (1977) 249-254
27. Ando R., Doi M., Yamauchi K., Chida Y., Ida T., Endo K., et al. Association of beta-fibrinogen and factor VII polymorphism with plasma fibrinogen and factor VII levels, and no association of PAI-1 polymorphism with plasma PAI-1 levels in hemodialysis patients. Clin Nephrol 58 (2002) 25-32
28. Lim B.C., Ariens R.A., Carter A.M., Weisel J.W., and Grant P.J. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 361 (2003) 1424-1431
29. Schmidt H., Schmidt R., Niederkorn K., Horner S., Becsagh P., Reinhart B., et al. Beta-fibrinogen gene polymorphism (C148→T) is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. Arterioscler.Thromb Vasc Biol 18 (1998) 487-492
30. Meschia J.F., Brott T.G., Brown Jr. R.D., Crook R.J., Frankel M., Hardy J., et al. The Ischemic Stroke Genetics Study (ISGS) Protocol. BMC Neurol 3 (2003) 4
31. Sherman D.G. Ancrod. Curr Med Res Opin 18 Suppl. 2 (2002) s48-s52